Rockville, Maryland, November 2, 2026 ( GlobeNewswire )– Supernus, Inc. (Nasdaq ticker: SUPN) Today, Supernus Pharmaceuticals, Inc announced that the merger with Indivior Pharmaceuticals, Inc has been successfully completed. This merger officially launches Supernus, Inc, a leading diversified biopharmaceutical company focused on treating patients with central nervous system (CNS) diseases.
Supernus, Inc. Bring immediate scalability and expansion capabilities.
- Diversified business platform: The company boasts a portfolio of 11 products that cover areas such as opioid use disorders, psychiatry, and neurology. Among these are five core growth drivers – SUBLOCADE ®, Qelbree ®, GOCOVRI ®, ONAPGO ®, and ZURZUVAE ® – which provide a solid foundation for long-term revenue expansion.
- Mature financial scale and enhanced cash flow: The company possesses the financial capability to pursue further growth opportunities, including driving the growth of its commercial product portfolio, advancing innovation initiatives, and undertaking future business developments.
Supernus, Inc. President and CEO Jack Khattar stated: "Today is a milestone of transformative significance as we officially integrate two organizations that have come together with a shared commitment to serving patients with complex neurological disorders. As a team, we are dedicated to expanding meaningful treatment options for patients, ensuring seamless execution, and bringing long-term value to our shareholders."
Supernus, Inc. The chairman of the board, Tony Kingsley, added: "This merger brings together first-class commercial capabilities, leading CNS therapies, and a strong financial foundation. We believe that the merged company will be able to maintain prudent capital allocation while pursuing long-term growth and is committed to creating value for shareholders."
Merger and transaction details
According to the terms of the final merger agreement, for each share of Supernus Pharmaceuticals and Inc held by the shareholders of Supernus Pharmaceuticals and Inc, they will be entitled to 1.5401 shares of Indivior Pharmaceuticals common stock.
As previously announced, shareholders holding Indivior shares prior to the merger and delivery will receive a one-time special cash dividend totaling 1 billion US dollars. To pay this dividend to the shareholders of Indivior, the two companies utilized a previously established debt commitment of 650 million US dollars. This financing came from a term loan arrangement provided by Citibank (Citibank N.A.), with the remaining amount to be paid from the existing cash of the merged company.
After the transaction is completed, based on a fully diluted basis, the original Indivior shareholders hold approximately 56.5% of the shares in the merged company, while the original Supernus Pharmaceuticals and Inc shareholders hold approximately 43.5%.
Management and Governance Structure
Supernus Pharmaceuticals's current headquarters in Rockville, Maryland, will serve as the global headquarters of the merged company. Jack Khattar will assume the roles of President, Chief Executive Officer, and Board Member of the merged company; Tony Kingsley, who previously served as a Board Member of Indivior, will become the Chairman of the Board. The board of directors of the merged company will consist of 8 members in total, with each of the two original companies nominating 4 directors.
Consultant
Cantor Fitzgerald and Co serve as the Chief Financial Advisors for Supernus Pharmaceuticals. Wells Fargo also acts as an additional financial advisor for Supernus Pharmaceuticals. Saul Ewing LLP serves as the legal advisor for Supernus Pharmaceuticals, while Morgan Lewis UK acts as its legal advisor for matters outside of the United States.
Jefferies LLC and Piper Sandler & Co serve as the joint financial advisors for Indivior. Goodwin Procter LLP acts as the legal advisor for Indivior. Citi also provides financial advice to Indivior. Citibank and N.A have provided committed financing support for this transaction.
For more information about this transaction, please visit the official website at Supernus.
Regarding Supernus, Inc.
Supernus, Inc is a leading diversified biopharmaceutical company focused on developing and commercializing therapies for the treatment of patients with central nervous system (CNS) diseases.
The company's commercial product portfolio includes approved therapies designed to support patients with opioid use disorder ( OUD ), attention deficit hyperactivity disorder ( ADHD ), dyskinesia in Parkinson's disease patients receiving levodopa treatment ( PD ), motor slowness in Parkinson's disease, postpartum depression ( PPD ), epilepsy, migraine, cervical dystonia, and chronic salivation, among others. Lending strength to its commercialization capabilities and scientific research expertise, the company states that it will continue to drive innovation and develop a robust pipeline of new product candidates to bring meaningful therapeutic outcomes to patients with CNS .
For more information, please visit: www.supernus.com.
Forward-looking Statements
This press release contains forward-looking statements. These statements are based on the current expectations, estimates, and assumptions of Supernus and are subject to risks and uncertainties. The forward-looking statements in this press release include, but are not limited to: the expected benefits of the merger with Indivior Pharmaceuticals and Inc, including anticipated synergies, cost savings, enhanced cash flow, financial flexibility, and scale, as well as the timing of realizing these benefits; the position of the combined company as a leading diversified central nervous system biopharmaceutical company; the expected listing of the combined company's common stock on the NASDAQ Global Market under the ticker “SUPN” beginning November 3, 2026, and the related delisting and relisting arrangements; the expected performance of the combined company's portfolio of 11 products, as well as the potential of five core growth-driven products to provide a solid foundation for long-term revenue expansion; the plans and capabilities of the combined company to advance its CNS product pipeline, seek strategic growth opportunities, and develop future business, and to allocate capital prudently to create shareholder value; the integration of the original Supernus and Indivior businesses; the timing and progress of clinical trials, as well as the obtaining and timing of regulatory approvals; the expansion of manufacturing capacity, including production by a second supplier of ONAPGO; and the future financial performance and expected expenditures of the combined company.
Forward-looking statements also include any other non-historical factual statements, including statements using words such as “expected,” “believed,” “estimated,” “anticipated,” “intended,” “planned,” “projected,” “goal,” “outlook,” “predicted,” “guideline,” “possible,” “will,” “shall,” “be able to,” “should,” and similar expressions, although not all forward-looking statements contain these words.
All forward-looking statements involve risks, uncertainties, and other factors that may lead to significant differences between actual results, performance, or achievements and those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to: the expected benefits from mergers, synergies, and cost savings may not be realized within the anticipated time frame, or may not be realized at all; the integration of Supernus Pharmaceuticals, Inc, Indivior Pharmaceuticals, and Inc.Difficulties and costs associated with the existing business, as well as the risk that integration may distract management attention or disrupt relationships with customers, payers, suppliers, or employees; the impact of the combined company's liabilities (including regular loan arrangements used to pay special cash dividends) on its financial results; the company's ability to maintain and improve profitability; the company's ability to raise sufficient capital to fully implement its corporate strategy; the execution of the company's strategy; the company's future financial performance and anticipated expenses; the company's ability to increase the number of prescriptions and net revenue for its products and those of its subsidiaries and to achieve commercialization; the company's future ability to collaborate with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the company's product research and development activities, including the timing and progress of clinical trials, as well as anticipated expenses; the company's ability to obtain regulatory approval to develop and commercialize product candidates or to have them produced by a second supplier ONAPGO; the company's ability to protect its own and its subsidiaries' intellectual property and to conduct business without infringing on the intellectual property of others; the company's expectations regarding federal, state, and overseas regulatory requirements; the therapeutic benefits, effectiveness, and safety of the company's product candidates; the accuracy of the company's estimates regarding the market size and characteristics that its product candidates can cover; the company's ability to enhance its products (including ONAPGO) and its manufacturing capabilities for product candidates; the company's expected market and market growth; the company's product formulations, patient needs, and potential sources of funding; the company's staffing requirements; changes in laws and regulations applicable to the industry; the impact of macroeconomic factors such as economic downturns or uncertainties, international conflicts, trade disputes, and tariffs; and other risks identified in the company's filings submitted to the U.S. Securities and Exchange Commission (SEC).
These forward-looking statements reflect the circumstances as of the date of this press release only. Except as required by applicable laws, Supernus, Inc shall not be obligated to update any forward-looking statements due to new information, future events, or other reasons.
Endnote
As part of the delivery process, Supernus Pharmaceuticals and Inc will be delisted from NASDAQ. The merged company, Supernus, is expected to begin trading under the code SUPN starting from November 3, 2026. The merged company, Supernus, will trade under the code INDV on November 2, 2026.
Supernus, Inc. Contact Information
Investor contacts: Peter Vozzo, ICR Healthcare, +1 443 213 0505, peter.vozzo @ icrhealthcare.com
Media contact: mediacontacts @ supernus.com
